Comparison of antibody responses induced by RV144, VAX003, and VAX004 vaccination regimens

AIDS Research and Human Retroviruses

Volumn 33, Issue 5, 2017, Pages 410-423

  Karnasuta, Chitraporn ^a   Akapirat, Siriwat ^a   Madnote, Sirinan ^a   Savadsuk, Hathairat ^a   Puangkaew, Jiraporn ^a   Rittiroongrad, Surawach ^a   Rerks Ngarm, Supachai ^b   Nitayaphan, Sorachai ^a   Pitisuttithum, Punnee ^c   Kaewkungwal, Jaranit ^d   Tartaglia, James ^e   Sinangil, Faruk ^f   Francis, Donald P ^f   Robb, Merlin L ^g,h   De Souza, Mark S ⁱ   Michael, Nelson L ^g   Excler, Jean Louis ^j   Kim, Jerome H ^j   O'connell, Robert J ^a   Karasavvas, Nicos ^a,g  

^a ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^b MINISTRY OF PUBLIC HEALTH   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d MAHIDOL UNIVERSITY   (Thailand)

^e SANOFI PASTEUR   (France)

^f Global Solutions for Infectious Diseases   (United States)

^g WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^h HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

ⁱ THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^j International Vaccine Institute   (South Korea)

more..

Author keywords

Antibodies; Gp120; HIV vaccines; HSV; IgG; IgG subclasses IgA; RV144; V1 V2; V2; V3; VAX003; VAX004

Indexed keywords

ERDOSTEINE; GLYCOPROTEIN D; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; UNCLASSIFIED DRUG; VAX 003; VAX 004; VIRUS ENVELOPE PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; CHO CELL LINE; COMPARATIVE STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HERPES SIMPLEX VIRUS; HIGH RISK POPULATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VACCINATION; VIRUS TRANSMISSION; ANTIBODY PRODUCTION; BLOOD; CLINICAL TRIAL; HUMAN; IMMUNOLOGY; VOLUNTEER;

AIDS VACCINES; ANTIBODY FORMATION; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; VOLUNTEERS;

EID: 85019154645     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2016.0204     Document Type: Article

References (45)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al.: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361: 2209-2220.
2. Robb ML, Rerks-Ngarm S, Nitayaphan S, et al.: Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: A post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis 2012;12: 531-537.
3. Haynes BF, Gilbert PB, McElrath MJ, et al.: Immunecorrelates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012;366: 1275-1286.
4. Kim JH, Excler JL, Michael NL: Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection. Annu Rev Med 2015;66: 423-437.
5. Zolla-Pazner S, Decamp A, Gilbert PB, et al.: Vaccineinduced IgG antibodies to V1 V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS One 2014;9: E87572.
6. Rolland M, Edlefsen PT, Larsen BB, et al.: Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 2012;490: 417-420.
7. Lin L, Finak G, Ushey K, et al.: COMPASS identifies Tcell subsets correlated with clinical outcomes. Nat Biotech 2015;33: 610-616.
8. de Souza MS, Ratto-Kim S, Chuenarom W, et al.: The Thai phase III Trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol 2012;188: 5166-5176.
9. Pitisuttithum P, Gilbert P, Gurwith M, et al.: Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194: 1661-1671.
10. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF: Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005;191: 654-665.
11. Francis DP, Gregory T, McElrath MJ, et al.: Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3. AIDS Res Hum Retroviruses 1998;14 Suppl 3: S325-S331.
12. Montefiori DC, Karnasuta C, Huang Y, et al.: Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 2012;206: 431-441.
13. Gilbert P, Wang M, Wrin T, et al.: Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J Infect Dis 2010;202: 595-605.
14. Karasavvas N, Billings E, Rao M, et al.: The Thai phase III HIV type 1 vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses 2012;28: 1444-1457.
15. Yates NL, Liao H-X, Fong Y, et al.: Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med 2014;6: 228ra239.
16. Zolla-Pazner S, deCamp AC, Cardozo T, et al.: Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One 2013;8: E53629.
17. Zolla-Pazner S, Edlefsen PT, Rolland M, et al.: Vaccineinduced human antibodies specific for the third variable region of HIV-1 gp120 impose immune pressure on infecting viruses. EBioMedicine 2014;1: 37-45.
18. Chung AW, Kumar MP, Arnold KB, et al.: Dissecting polyclonal vaccine-induced humoral immunity against HIV using systems serology. Cell 2015;163: 988-998.
19. Berman PW: Development of bivalent rgp120 vaccines to prevent HIV type 1 infection. AIDS Res Hum Retroviruses 1998;14 Suppl 3: S277-S289.
20. Lasky LA, Groopman JE, Fennie CW, et al.: Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science 1986;233: 209-212.
21. Kayman SC, Wu Z, Revesz K, Chen H, Kopelman R, Pinter A: Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains. J Virol 1994;68: 400-410.
22. Pinter A, Honnen WJ, Kayman SC, Trochev O, Wu Z: Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120. Vaccine 1998;16: 1803-1811.
23. Weiss H: Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes 2004;11 Suppl 1: 24A-35A.
24. Holtz TH, Thienkrua W, McNicholl JM, et al.: Prevalence of Treponema pallidum seropositivity and herpes simplex virus type 2 infection in a cohort of men who have sex with men, Bangkok, Thailand, 2006-2010. Int J STD AIDS 2012; 23: 424-428.
25. Corey L, Wald A, Celum CL, Quinn TC: The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: A review of two overlapping epidemics. J Acquir Immune Defic Syndr 2004;35: 435-445.
26. Gupta R, Warren T, Wald A: Genital herpes. Lancet 2007;370: 2127-2137.
27. Biraro S, Kamali A, White R, et al.: Effect of HSV-2 on population-level trends in HIV incidence in Uganda between 1990 and 2007. Trop Med Int Health 2013;18: 1257-1266.
28. Gottardo R, Bailer RT, Korber BT, et al.: Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One 2013;8: E75665.
29. Peachman KK, Karasavvas N, Chenine A-L, et al.: Identification of new regions in HIV-1 gp120 variable 2 and 3 loops that bind to a4b7 integrin receptor. PLoS One 2015; 10: E0143895.
30. O'Connell RJ, Kim JH, Excler JL: The HIV-1 gp120 V1 V2 loop: Structure, function and importance for vaccine development. Expert Rev Vaccines 2014;13: 1489-1500.
31. Tomaras GD, Ferrari G, Shen X, et al.: Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A 2013;110: 9019-9024.
32. Go VF, Frangakis C, Nam le V, et al.: High HIV sexual risk behaviors and sexually transmitted disease prevalence among injection drug users in Northern Vietnam: Implications for a generalized HIV epidemic. J Acquir Immune Defic Syndr 2006;42: 108-115.
33. Forthal D, Hope TJ, Alter G: New paradigms for functional HIV-specific nonneutralizing antibodies. Curr Opin HIV AIDS 2013;8: 393-401.
34. Roussilhon C, Oeuvray C, Muller-Graf C, et al.: Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. PLoS Med 2007;4: E320.
35. Kam YW, Simarmata D, Chow A, et al.: Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection. J Infect Dis 2012;205: 1147-1154.
36. Banerjee K, Klasse PJ, Sanders RW, et al.: IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines. AIDS Res Hum Retroviruses 2010;26: 445-458.
37. Gorse GJ, Corey L, Patel GB, et al.: HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses 1999;15: 115-132.
38. Chung AW, Ghebremichael M, Robinson H, et al.: Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci Transl Med 2014;6: 228ra238.
39. Aalberse RC, van der Gaag R, van Leeuwen J: Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J Immunol 1983;130: 722-726.
40. Akapirat S, Vasan S, Pitisuttithum P, et al.: Specific IgG subclasses induced in RV305: A late boost vaccination of RV144 subjects. In: The Annual Conference on Retroviruses and Opportunistic Infections (CROI).Boston,MA;Abstract 318; 2016.
41. Williams L, Yates NL, Lucas J, et al.: IgG3 subclass and specificity profiles elicited by the RV305 vaccine regimen. Keystone: HIV Vaccines. Banff, Alberta, Canada, Abstract 5-2016;2015.
42. Goepfert PA, Tomaras GD, Horton H, et al.: Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine 2007;25: 510-518.
43. Excler JL, Tomaras GD, Russell ND: Novel directions in HIV-1 vaccines revealed from clinical trials. Curr Opin HIV AIDS 2013;8: 421-431.
44. Amanna IJ, Carlson NE, Slifka MK: Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007;357: 1903-1915.
45. Amanna IJ, Slifka MK: Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev 2010;236: 125-138.